Copyright © Queen's Printer,

Victoria, British Columbia, Canada

Licence

Disclaimer

Volume 51, No. 13

B.C. Reg. 200/2008

The British Columbia Gazette,

Part II

July 1, 2008

B.C. Reg. 200/2008 , deposited June 27, 2008, pursuant to the PHARMACISTS, PHARMACY OPERATIONS AND DRUG SCHEDULING ACT [Section 64]. Order in Council 529/2008, approved and ordered June 26, 2008.

On the recommendation of the undersigned, the Lieutenant Governor, by and with the advice and consent of the Executive Council, orders that the amendments to the Drug Schedules Regulation, B.C. Reg. 9/98, set out in the Resolutions of the Council of the College of Pharmacists of British Columbia listed below and attached to this order, are approved:

Resolution No. February 9, 2007

Resolution No. September 21, 2007

Resolution No. November 23, 2007

Resolution No. February 15, 2008

— G. ABBOTT, Minister of Health; G. CAMPBELL, Presiding Member of the Executive Council.

Resolution of the Council of the College of Pharmacists of British Columbia ("the Council"), made at Vancouver, British Columbia, the 9th day of February 2007.

RESOLVED THAT:

In accordance with the authority established in

Section 64 of the Pharmacists, Pharmacy Operations and Drug Scheduling Act , R.S.B.C. 1996, c. 363 of British Columbia, the Council amends the Drug Schedules Regulation as set out in the attached schedule, subject to the approval of the Lieutenant Governor in Council.

Certified a true copy

Marshall Moleschi, B.Sc. (Pharm), MHA

Registrar

Schedule

That the Drug Schedules Regulation be amended by the deletion of:

1 Adrenocortical hormones and their salts and derivatives, (except hydrocortisone or hydrocortisone acetate, when sold as a single medicinal ingredient in a concentration that provides 0.5% or less hydrocortisone in preparations for topical use on the skin) v

1 Vitamin K v

and the addition of:

1 Adefovir and its salts and derivatives

1 Adrenocortical hormones and their salts and derivativesv (except

(

a) hydrocortisone or hydrocortisone acetate, when sold as a single medicinal ingredient in a concentration that provides 0.5% or less hydrocortisone in preparations for topical use on the skin and

(

b) clobetasone butyrate, when sold in a concentration of 0.05% clobetasone butyrate in cream preparations for topical use on the skin)

1 Almotriptan and its salts

1 Cetrorelix and its salts

1 Ketanserin and its salts

1 Phenylpropanolamine and its salts and derivatives for veterinary use

1 Tadalafil and its salts

1 Teflubenzuron

1 Vitamin K V (except Vitamin K1 and Vitamin K2 sold

(

a) for external use in humans, or

(

b) in an oral dosage form for use in humans if the maximum recommended daily dose is 0.120 mg or less)

Schedule

Council rescinds the Drug Schedules Regulation resolution approved at the November 24, 2006 council meeting and recommends the Drug Schedules Regulation be amended by the:

Deletion of:

3 Dextromethorphan and its salts (except in oral dosage forms in package sizes containing no more than 300 mg)

2 Diphenhydramine and its salts (for parenteral or topical use)

3 Diphenhydramine and its salts and preparations (for oral use)

2 Gramicidin and its salts and derivatives (for ophthalmic use)

1 Ivermectin and its derivatives, for human use or for veterinary use when sold for intramuscular injection into horses or for oral administration to dogs and cats

1 Ketamine and its salts

1 Metropolol and its salts

2 Nicotine and its salts, for human use, except

(

a) in natural substances;

(

b) in the form of a chewing gum containing 4 mg or less of nicotine per dosage unit;

(

c) in the form of a transdermal patch with a delivery rate of 22 mg or less of nicotine per day; or

(

d) in a form to be administered orally by means of an inhalation device delivering 4 mg or less of nicotine per dosage unit

and the addition of:

1 Anti-thymocyte globulin

1 Atazanavir and its salts

1 Bivalirudin

1 Bortezomib

2 Clobetasone butyrate (when sold in a concentration of 0.05% clobetasone butyrate in cream preparations for topical use on the skin)

1 Danofloxacin and its salts

3 Dextromethorphan and its salts (except in oral dosage forms in package sizes containing no more than 300 mg dextromethorphan base or 409.3 dextromethorphan hydrobromide)

2 Diphenhydramine and its salts and preparations (for parenteral use or for topical use in concentrations of greater than 2%)

3 Diphenhydramine and its salts and preparations (except for parenteral use or for topical use in concentrations of 2% or less)

1 Drotrecogin

1 Enfuvirtide

1 Ertapenem and its salts

1 Ezetimibe

1 Fondaparinux sodium

1 Formoterol and its salts

1 Fulvestrant

1 Gefitinib

1 Gemifloxacin and its salts

3 Gramicidin and its salts and derivatives (for ophthalmic use)

1 Hetastarch and its derivatives

1 Ibandronic acid and its salts

1 Ivermectin and its derivatives (for human use or for veterinary use when sold for intramuscular injection into horses or for administration to dogs and cats)

1 Levetiracetam

1 Memantine and its salts

1 Metoprolol and its salts

1 Modafinil and its salts

1 Nicotine and its salts, for human use, except

(

a) in natural substances;

(

b) in the form of a chewing gum containing 4 mg or less of nicotine per dosage unit;

(

c) in the form of a transdermal patch with a delivery rate of 22 mg or less of nicotine per day;

(

d) in a form to be administered orally by means of an inhalation device delivering 4 mg or less of nicotine per dosage unit; or

(

e) in the form of a lozenge containing 4 mg or less of nicotine per dosage unit

1 Pimecrolimus

1 Ponazuril

1 Rosuvastatin and its salts

1 Sibutramine and its salts

1 Telithromycin and its salts and derivatives

1 Tenofovir and its salts and derivatives

1 Treprostinil and its salts

Schedule

Council rescinds the Drug Schedules Regulation resolution approved at the September 22, 2006 council meeting and recommends the Drug Schedules Regulation be amended by the:

Deletion of:

2 Bacitracin and its salts and derivatives (for ophthalmic use)

2 Gramicidin and its salts and derivatives (for ophthalmic use)

2 Lidocaine and its salts (for ophthalmic, otic or parenteral use, or for topical use on mucous membranes, except lozenges)

2 Polymixin B and its salts and derivatives (for ophthalmic use)

and the addition of:

3 Bacitracin and its salts and derivatives (for ophthalmic use)

3 Gramicidin and its salts and derivatives (for ophthalmic use)

2 Lidocaine and its salts (for ophthalmic or parenteral use, or topical use on mucous membranes, except lozenges)

3 Lidocaine and its salts (for otic use)

3 Polymyxin B and its salts and derivatives (for ophthalmic use)

Resolution of the Council of the College of Pharmacists of British Columbia ("the Council"), made at Vancouver, British Columbia, the 21st day of September 2007.

RESOLVED THAT:

In accordance with the authority established in

Section 64 of The Pharmacists, Pharmacy Operations and Drug Scheduling Act , R.S.B.C. 1996, c. 363 of British Columbia, the Council amends the Drug Schedules Regulation as set out in the attached schedule, subject to the approval of the Lieutenant Governor in Council.

Certified a true copy

Marshall Moleschi, B.Sc. (Pharm), MHA

Registrar

Schedule

That the Drug Schedules Regulation be amended by the addition of:

Addition of:

1 Agalsidase alfa

1 Botulinum Toxin Type B

3 Isopropyl myristate in concentration of 50% (for use in the treatment of head lice)

1 Laronidase

1 Miglustat

1 Muromonab-CD3

1 Pegfilgrastim

1 Pemetrexed and its salts

1 Rasburicase

1 Teriparatide and its salts

1 Vardenafil and its salts

Resolution of the Council of the College of Pharmacists of British Columbia ("the Council"), made at Vancouver, British Columbia, the 23rd day of November 2007.

RESOLVED THAT:

In accordance with the authority established in

Section 64 of The Pharmacists, Pharmacy Operations and Drug Scheduling Act , R.S.B.C. 1996, c. 363 of British Columbia, the Council amends the Drug Schedules Regulation as set out in the attached schedule, subject to the approval of the Lieutenant Governor in Council.

Certified a true copy

Marshall Moleschi, B.Sc. (Pharm), MHA

Registrar

SCHEDULE

That the Drug Schedules Regulation be amended by the deletion of:

3 Ibuprofen and its salts (when sold in strengths greater than 200 mg, but less than or equal to 400 mg, per solid dosage form or per 5mL liquid dosage form)

Resolution of the Council of the College of Pharmacists of British Columbia ("the Council"), made at Vancouver, British Columbia, the l5th day of February 2008.

RESOLVED THAT:

In accordance with the authority established in

Section 64 of The Pharmacists, Pharmacy Operations and Drug Scheduling Act , R.S.B.C. 1996, c. 363 of British Columbia, the Council amends the Drug Schedules Regulation as set out in the attached schedule, subject to the approval of the Lieutenant Governor in Council.

Certified a true copy

Marshall Moleschi, B.Sc. (Pharm), MHA

Registrar

Schedule

Council rescinds the Drug Schedules Regulation resolution approved at the May 4, 2007 council meeting and recommends the Drug Schedules Regulation be amended by the:

Deletion of:

1 Famotidine and its salts (except in preparations for oral use containing 10 mg or less of famotidine per dosage unit)

3 Fexofenadine hydrochloride

3 Hydrocortisone (as a single ingredient in topical preparations in concentration of 0.5% or less)

1 Hydrocortisone v (except as a single ingredient in topical preparations in concentrations of 0.5% or less)

3 Hydrocortisone acetate (as a single ingredient in topical preparations in concentrations of 0.5% or less)

1 Hydrocortisone acetate v (except as a single ingredient in topical preparations in concentrations of 0.5% or less)

2 Loperamide and its salts (oral liquid dosage forms for children)

2 Loperamide and its salts (in other than solid dosage forms)

1 Ranitidine and its salts (except oral tablets in strengths of 75 mg or less)

Addition of:

1 Adalimumab

1 Alefacept

1 Alemtuzumab

1 Atomoxetine and its salts

1 Azelaic acid

1 Bevacizumab

1 Cetuximab

1 Choriogonadotropin alia

1 Cinacalcet and its salts

1 Darifenacin and its salts

1 Efalizumab

1 Eletriptan and its salts

1 Emtricitabine

1 Escitalopram and its salts

1 Famotidine and its salts (except when sold in concentrations of 20 mg or less per oral dosage unit and indicated for the treatment of heartburn)

2 Famotidine and its salts (when sold in concentrations of 20 mg or less per oral dosage unit and indicated for the treatment of heartburn, in package sizes containing more than 600 mg of famotidine)

3 Fexofenadine hydrochloride (in products marketed for pediatric use — under 12 years of age)

1 Frovatriptan and its salts

1 Hydrocortisone v (except when sold as a single medicinal ingedient in a concentration that provides 0.5% hydrocortisone in preparations for topical use on the skin)

3 Hydrocortisone (when sold as a single medicinal ingredient in a concentration that provides 0.5% hydrocortisone in preparations for topical use on the skin)

1 Hydrocortisone acetate V (except when sold as a single medicinal ingredient in a concentration that provides 0.5% hydrocortisone in preparations for topical use on the skin)

3 Hydrocortisone acetate (when sold as a single medicinal ingredient in a concentration that provides 0.5% hydrocortisone in preparations for topical use on the skin)

2 Loperamide and its salts (in products marketed for pediatric use — under 12 years of age)

1 Nitric oxide

1 Omalizumab

1 Palifermin

1 Paricalcitol

1 Pegaptanib and its salts

1 Pegvisomant

1 Ranitidine and its salts (except when sold in concentrations of 150 mg or less per oral dosage unit and indicated for the treatment of heartburn)

3 Ranitidine and its salts (when sold in concentrations of 150 mg or less per oral dosage unit and indicated for the treatment of heartburn, in package sizes containing more than 4 500 mg of ranitidine)

1 Tipranavir and its salts

1 Voriconazole

Copyright © 2008: Queen's Printer, Victoria, British Columbia, Canada